Duration of Disease and Long‐Term Outcomes in Patients With Difficult‐To‐Treat Recurrent Pericarditis: A Chronic Condition Treated With Nonsteroidal Anti‐Inflammatory Drugs, Colchicine, Corticosteroids, and Anti–Interleukin‐1 Agents
Authors:
Open Access
- 23 January 2025
- journal article
- research article
- Published by Wiley in ACR Open Rheumatology
- Vol. 7 (1) , e11776
Abstract
Objective: We aimed to investigate the remission rate and disease duration in idiopathic or post–cardiac injury pericarditis and risk factors for disease duration and anti–interleukin‐1 (IL‐1) agent discontinuation.Methods: This was a multicenter, longitudinal, observational study including 370 patients (51.4% female). The remission rate was the proportion of patients who stopped all pericarditis‐related therapies for at least 6 months without recurrences.Results: The median follow‐up was 4.9 (interquartile range [IQR] 2.8–8.4) years, and the median age at the end of follow‐up was 49 (IQR 37–60) years. A median of 1.1 (IQR 0.6–1.9) recurrences/year and 0.4 (IQR 0.1–0.9) hospitalizations/year were recorded. The remission rate at follow‐up was 34.0%, 7% per year. Disease duration was shorter for patients in remission (3.1 years, IQR 1.6–6.2 years) than for those still receiving treatment (4 years, IQR 2.2–7.8; P = 0.02). Use of “guidelines‐based therapy” (hazard ratio [HR] 1.85, 95% confidence interval [CI] 1.25–2.73; P = 0.02) and colchicine use at first attack (HR 1.51, 95% CI 1.02–2.23; P = 0.038) were protective factors, whereas steroid use was associated with longer disease duration (HR 0.53, 95% CI 0.35–0.81; P = 0.003). Corticosteroids were used in 77.3% of patients, with a median duration of therapy of 1.1 (IQR 0.4–2.6) years. Anakinra was used in 25.9% with a median duration of therapy of 2.4 (IQR 0.9–5.0) years; only 19.8% were able to stop anakinra at the end of observation period.Conclusion: This study reports the largest and longest follow‐up in patients with recurrent pericarditis. Guideline adherence from the first attack is associated with a shorter course. The disease was long and impacting in terms of recurrences and hospitalizations, often requiring a long‐term treatment, in particular with anti–IL‐1 agents. imageKeywords
Funding Information
- Kiniksa Pharmaceuticals
This publication has 33 references indexed in Scilit:
- Perioperative management of drugs commonly used in patients with rheumatic diseases: a reviewClinics, 2017
- Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid DependenceJAMA, 2016
- Reasons for intentional guideline non-adherence: A systematic reviewInternational Journal of Medical Informatics, 2016
- 2015 ESC Guidelines for the diagnosis and management of pericardial diseasesEuropean Heart Journal, 2015
- EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseasesAnnals of the Rheumatic Diseases, 2013
- A Randomized Trial of Colchicine for Acute PericarditisNew England Journal of Medicine, 2013
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesJournal of Clinical Epidemiology, 2008
- Prognosis of Idiopathic Recurrent Pericarditis as Determined from Previously Published ReportsThe American Journal of Cardiology, 2007
- Long-Term Outcomes in Difficult-to-Treat Patients With Recurrent PericarditisThe American Journal of Cardiology, 2006
- Recurrent acute pericarditis: Follow-up study of 31 patientsJACC, 1986